VYGR

SEC filing VYGR Receives FDA Clearance for VY1706 IND, Plans Phase 1 Trial for Alzheimer's Gene Therapy

1d ago

News Voyager Therapeutics CFO resigns; Robin Swartz takes financial charge

41d ago

SEC filing VYGR Resigns CFO Jorgensen, Appoints Swartz CFO, Quinlan PACCO

41d ago

SEC filing VYGR Reports $15.3M Q4 Revenue, $134.7M R&D Spend, $202M Cash Runway to 2028, VY1706 GLP Study Q1 2026, VY7523 MAD Completion, NeuroShuttle Proof-of-Concept

84d ago

Insider trade Sale by Nathan D. Jorgensen (Chief Financial Officer)

95d ago

Insider trade Sale by Todd Alfred Carter (Chief Scientific Officer)

95d ago

Insider trade Sale by Alfred Sandrock (President and CEO)

95d ago

Insider trade Sale by Robin Swartz (COO & CBO)

95d ago